Novartis AG
Substituted bisphenyl butanoic ester derivatives as NEP inhibitors

Abstract:

The present disclosure provides a compound of Formula (I); ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 and R.sup.2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.